Document is current
Any future updates will be listed below
-
Authors
Roberts, Jessica P.
Tang, Abby F.
Hernandez, Daniela
Carman, Brianna
Oiknine, Liam
Brown, Cris
Hurst, Stacy
Tang, Yunshuo
Urano, Fumihiko https://orcid.org/0000-0002-9944-6293
-
Funding
Funding for this research was provided by:
National Institute of Diabetes and Digestive and Kidney Diseases (DK132090)
National Institute of Diabetes and Digestive and Kidney Diseases (DK020579)
National Center for Advancing Translational Sciences (UL1TR002345)
- License Information
-
More Information
Article History
Received: 4 November 2025
Accepted: 4 April 2026
First Online: 18 April 2026
Declarations
:
: FU has a sponsored research agreement and has received material support from Prilenia Therapeutics. He is the current principal investigator of the Phase 2 clinical trial of AMX0035 in patients with Wolfram syndrome, sponsored by Amylyx Pharmaceuticals. He has received grants from the National Institutes of Health (NIH) and royalties from Novus Biologicals and Sana Biotechnology. He has also received licensing and/or consulting fees from Opris Biotechnologies and Emerald Biotherapeutics, and travel support from Wolfram France, Wolfram UK, and the Snow Foundation. He serves in unpaid advisory roles for the Snow Foundation and the Be A Tiger Foundation. He holds U.S. patents (9,891,231; 10,441,574; 10,695,324) and was previously President and a shareholder of the now-dissolved CURE4WOLFRAM.
